Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763093 | 0.90 | BCL9 (0.54) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL19315980 | 0.88 | BCL9 (0.48) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL903436 | 0.88 | BCL9 (0.52) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL6348996 | 0.88 | BCL9 (0.56) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL31488048 | 0.87 | BCL9 (0.51) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL6348206 | 0.87 | BCL9 (0.51) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL2721373 | 0.86 | BCL9 (0.50) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL3371416 | 0.86 | BCL9 (0.50) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL1461897 | 0.84 | ELANE (0.60) | BCL9CTNNB1GAAMGLLHTR2A | |
| SCHEMBL2802479 | 0.84 | MGLL (0.57) | BCL9CTNNB1GAAMGLLHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230097252-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2020247736-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2020-12-10 | — | — | WO | disclosed |
| US-10815194-B2 | Process for the preparation of mono-protected α,ω-diamino alkanes | BYONDIS B.V. (NL) | 2020-10-27 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-6911549-B1 | Method of preparing a taxol derivative | SANOFI (FR) | 2005-06-28 | — | — | US | disclosed |
| EP-1411933-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-0674630-B1 | 7-HALO- AND 7$g(b),8$g(b)-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UPJOHN CO (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-0703909-B1 | DELTA 6,7 -TAXOLS ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UPJOHN CO (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0982302-A2 | Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-01 | — | — | EP | disclosed |
| EP-0982301-A2 | Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-01 | — | — | EP | disclosed |
| US-5965739-A | OXAZOLIDINE PROTECTED TAXOL ANALOGS OF GIVEN FORMULA, AND METHODS OF SYNTHESIS FROM AN OXAZOLIDINE FREE ACID AND A BACCATIN COMPOUND IN THE PRESENCE OF A DEHYDRATING AGENT; USEFUL INTERMEDIATES TO MAKE VARIOUS TAXOL ANALOGUES | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| US-5556878-A | Δ6,7 -taxols antineoplatic use and pharmaceutical compositions containing them | THE UPJOHN COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| EP-0703909-A1 | $g(D)?6,7 -TAXOLS ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY (US) | 1996-04-03 | — | — | EP | disclosed |
| EP-0674630-A1 | 7-HALO- AND 7$g(b),8$g(b)-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994029288-A1 | Δ6,7-TAXOLS ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE UPJOHN COMPANY (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994013655-A1 | 7-HALO- AND 7β,8β-METHANO-TAXOLS, ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE UPJOHN COMPANY (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097252-A1 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | LIG1, LIG3, STUB1 | BCL9 1388/4885CTNNB1 4336/4885GAA 1069/4885 |
| US-10815194-B2 | Process for the preparation of mono-protected α,ω-diamino alkanes | FCGRT, CD22, DEGS1 | BCL9 2011/4885CTNNB1 1884/4885GAA 716/4885 |
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | BCL9 807/4885CTNNB1 1528/4885GAA 294/4885 |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | BCL9 807/4885CTNNB1 1528/4885GAA 294/4885 |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MALT1, ALG1, PRMT3 | BCL9 768/4885CTNNB1 4834/4885GAA 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.